4 active not recruiting, 4 completed, 3 recruiting, 2 withdrawn. 14 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Active not recruiting 4, Completed 4, Recruiting 3, Withdrawn 2, Unknown 1 |
| Phase 2 | 3 | Completed 1, Recruiting 1, Unknown 1 |
Follow Recurrent Medulloblastoma: new trials by email Literature Review of Recurrent Medulloblastoma trials Research Report on Recurrent Medulloblastoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS) 25 mCi 177Lu- DTPA-omburtamab - Recurrent Medulloblastoma, Refractory Medulloblastoma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 24 | 2026-07-02 | 2026-10-08 |
| RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB) Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs) - Recurrent Medulloblastoma | Phase 1 | Active not recruiting | University of Florida | 24 | 2026-04-24 | 2026-09-29 |
| GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults GPC2-CAR T cells, Fludarabine, Cyclophosphamide - Medulloblastoma, Central Nervous System Embryonal Tumor | Phase 1 | Recruiting | Stanford University | 18 | 2025-08-28 | 2026-10-09 |
| Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies Nivolumab, Methotrexate, 5-Azacytidine - Recurrent Ependymoma, Recurrent Medulloblastoma | Phase 1 | Withdrawn | Jeffrey Treiber | 2024-07-15 | 2026-01-08 | |
| Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors LUTATHERA® (Lutetium Lu 177 dotatate) - High Grade Glioma, Meningioma | Phase 1 / Phase 2 | Recruiting | Nationwide Children's Hospital | 65 | 2022-11-21 | 2026-07-20 |
| Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer Etoposide, Fludarabine Phosphate, Hematopoietic Cell Transplantation - Anaplastic Ependymoma, Atypical Teratoid/Rhabdoid Tumor | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2021-01-14 | 2024-10-26 | |
| Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors Biospecimen Collection, Magnetic Resonance Imaging, Savolitinib - Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Malignant Glioma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 41 | 2018-11-27 | 2026-07-30 |
| PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma PEP-CMV - Recurrent Medulloblastoma, Recurrent Brain Tumor, Childhood | Phase 1 | Active not recruiting | Daniel Landi | 30 | 2018-06-29 | 2026-06-18 |
| SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors Gemcitabine, ribociclib, sonidegib - Anaplastic Astrocytoma, Anaplastic Ependymoma | Phase 1 | Completed | St. Jude Children's Research Hospital | 68 | 2018-03-05 | 2024-05-31 |
| Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors Everolimus, Laboratory Biomarker Analysis, Pharmacological Study - CNS Embryonal Tumor, Not Otherwise Specified, Malignant Glioma | Phase 1 | Completed | Pediatric Brain Tumor Consortium | 22 | 2018-01-13 | 2021-08-27 |
| Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma Biospecimen Collection, Conventional Magnetic Resonance Imaging, Diffusion Tensor Imaging - Constitutional Mismatch Repair Deficiency Syndrome, Lynch Syndrome | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 71 | 2015-06-03 | 2026-07-20 |
| Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors Laboratory Biomarker Analysis, Natural Killer Cell Therapy - Recurrent Childhood Medulloblastoma, Recurrent Ependymoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 12 | 2015-03-17 | 2020-09-02 |
| Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors Adavosertib, Irinotecan Hydrochloride - Central Nervous System Embryonal Tumor With Rhabdoid Features, Central Nervous System Embryonal Tumor, Not Otherwise Specified | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 76 | 2014-03-28 | 2023-09-26 |
| Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors Carboplatin, Mannitol, Melphalan - Central Nervous System Embryonal Neoplasm, Embryonal Tumor With Multilayered Rosettes, C19MC-Altered | Phase 1 / Phase 2 | Unknown | OHSU Knight Cancer Institute | 17 | 2009-07-09 | 2021-10-26 |
Medulloblastoma (14) · Glioma (7) · Ependymoma (6) · Brain Neoplasms (5) · Central Nervous System Neoplasms (5) · Neuroectodermal Tumors, Primitive (5) · Diffuse Intrinsic Pontine Glioma (4) · Rhabdoid Tumor (4) · Neoplasms, Germ Cell and Embryonal (3) · Pinealoma (3) · Choroid Plexus Carcinoma (2) · Familial ependymoma (2) · Meningioma (2) · Astrocytoma (1) · Colorectal Neoplasms, Hereditary Nonpolyposis (1)
Neoplasms by Histologic Type (14) · Neoplasms, Glandular and Epithelial (14) · Neoplasms, Nerve Tissue (14) · Neuroectodermal Tumors (14) · Neoplasms (13) · Neoplasms, Neuroepithelial (13) · Neoplasms, Germ Cell and Embryonal (11) · Neoplasms by Site (10) · Nervous System Diseases (10) · Nervous System Neoplasms (10) · Brain Diseases (9) · Central Nervous System Diseases (9) · Neuroectodermal Tumors, Primitive (9) · Glioma (7) · Central Nervous System Neoplasms (5)
Magnetic Resonance Spectroscopy (2) · Melphalan (2) · Specimen Handling (2) · ribociclib (2) · 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine (1) · Antilymphocyte Serum (1) · Azacitidine (1) · Carboplatin (1) · Cyclophosphamide (1) · Diffusion Tensor Imaging (1) · Etoposide (1) · Everolimus (1) · Filgrastim (1) · Gemcitabine (1) · Granulocyte Colony-Stimulating Factor (1)
National Cancer Institute (NCI) (3) · M.D. Anderson Cancer Center (2) · Daniel Landi (1) · Jeffrey Treiber (1) · Memorial Sloan Kettering Cancer Center (1) · Nationwide Children's Hospital (1) · OHSU Knight Cancer Institute (1) · Pediatric Brain Tumor Consortium (1) · St. Jude Children's Research Hospital (1) · Stanford University (1) · University of Florida (1)
United States (12) · Canada (3)
Daniel Landi, MD (1) · Edward A Neuwelt (1) · Elias Sayour, MD, PhD (1) · Eugene I Hwang (1) · Giles W. Robinson, MD (1) · Jeffrey M. Treiber, MD (1) · Katherine Ryan, DO (1) · Kris M Mahadeo, MD (1) · Kristina A Cole (1) · Margot Lazow, MD (1) · Mariko D. DeWire-Schottmiller, MD (1) · Ralph Salloum (1) · Sabine Mueller, MD, PhD (1) · Sameer Farouk Sait, MBBS (1) · Soumen Khatua (1)
UM1CA081457 (3), P30CA016672 (1), R01NS044687 (1), UM1CA097452 (1)